APO Research

APO RESEARCH · REPORT

RNA Transcriptome Profiling Test

Selected research

Market Outlook & Growth Opportunities

Global RNA Transcriptome Profiling Test Market Outlook and Growth Opportunities 2026

Market perspective

The global RNA Transcriptome Profiling Test market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for RNA Transcriptome Profiling Test is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for RNA Transcriptome Profiling Test is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for RNA Transcriptome Profiling Test is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the RNA Transcriptome Profiling Test market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the RNA Transcriptome Profiling Test market include Thermo Fisher Scientific, Inc., Illumina, Inc., Agilent Technologies, Inc., QIAGEN N.V., F. Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., Merck KGaA, Eurofins Scientific and Pacific Biosciences of California, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global RNA Transcriptome Profiling Test market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of RNA Transcriptome Profiling Test and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents RNA Transcriptome Profiling Test revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global RNA Transcriptome Profiling Test market.

RNA Transcriptome Profiling Test Segment by Company

Thermo Fisher Scientific, Inc.

Illumina, Inc.

Agilent Technologies, Inc.

QIAGEN N.V.

F. Hoffmann-La Roche AG

Bio-Rad Laboratories, Inc.

Merck KGaA

Eurofins Scientific

Pacific Biosciences of California, Inc.

Promega Corporation

10x Genomics

Twist Bioscience

Bruker Spatial Biology

RNA Transcriptome Profiling Test Segment by Type

Consumables

Instruments

Software

Services

RNA Transcriptome Profiling Test Segment by Application

Hospital Based Laboratories

Diagnostic Centers

Academic and Research Institutes

Contract research Organizations (CROs)

Others

RNA Transcriptome Profiling Test Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global RNA Transcriptome Profiling Test status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the RNA Transcriptome Profiling Test key companies, revenue, market share, and recent developments.

3. To split the RNA Transcriptome Profiling Test breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions RNA Transcriptome Profiling Test market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify RNA Transcriptome Profiling Test significant trends, drivers, influence factors in global and regions.

6. To analyze RNA Transcriptome Profiling Test competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNA Transcriptome Profiling Test market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of RNA Transcriptome Profiling Test and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNA Transcriptome Profiling Test.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global RNA Transcriptome Profiling Test industry.

Chapter 3: Detailed analysis of RNA Transcriptome Profiling Test company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of RNA Transcriptome Profiling Test in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of RNA Transcriptome Profiling Test in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. RNA Transcriptome Profiling Test Industry Trends Table 2. RNA Transcriptome Profiling Test Industry Drivers Table 3. RNA Transcriptome Profiling Test Industry Opportunities and Challenges Table 4. RNA Transcriptome Profiling Test Industry Restraints Table 5. Global RNA Transcriptome Profiling Test Revenue by Company (US$ Million) & (2021-2026) Table 6. Global RNA Transcriptome Profiling Test Revenue Share by Company (2021-2026) Table 7. Global RNA Transcriptome Profiling Test Company Ranking, (2024-2026) & (US$ Million) Table 8. Global RNA Transcriptome Profiling Test Key Company Manufacturing Base & Headquarters Table 9. Global RNA Transcriptome Profiling Test Company, Product Type & Application Table 10. Global RNA Transcriptome Profiling Test Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global RNA Transcriptome Profiling Test by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Consumables Table 15. Significant Companies of Instruments Table 16. Significant Companies of Software Table 17. Significant Companies of Services Table 18. Global RNA Transcriptome Profiling Test Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global RNA Transcriptome Profiling Test Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global RNA Transcriptome Profiling Test Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global RNA Transcriptome Profiling Test Sales Value Share by Type (2021-2026) Table 22. Global RNA Transcriptome Profiling Test Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital Based Laboratories Table 24. Significant Companies of Diagnostic Centers Table 25. Significant Companies of Academic and Research Institutes Table 26. Significant Companies of Contract research Organizations (CROs) Table 27. Significant Companies of Others Table 28. Global RNA Transcriptome Profiling Test Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global RNA Transcriptome Profiling Test Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global RNA Transcriptome Profiling Test Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global RNA Transcriptome Profiling Test Sales Value Share by Application (2021-2026) Table 32. Global RNA Transcriptome Profiling Test Sales Value Share by Application (2027-2032) Table 33. Global RNA Transcriptome Profiling Test Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global RNA Transcriptome Profiling Test Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global RNA Transcriptome Profiling Test Sales Value Share by Region (2021-2026) Table 36. Global RNA Transcriptome Profiling Test Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global RNA Transcriptome Profiling Test Sales Value Share by Region (2027-2032) Table 38. Global RNA Transcriptome Profiling Test Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global RNA Transcriptome Profiling Test Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global RNA Transcriptome Profiling Test Sales Value Market Share by Country (2021-2026) Table 41. Global RNA Transcriptome Profiling Test Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global RNA Transcriptome Profiling Test Sales Value Market Share by Country (2027-2032) Table 43. Thermo Fisher Scientific, Inc. Company Information Table 44. Thermo Fisher Scientific, Inc. Business Overview Table 45. Thermo Fisher Scientific, Inc. RNA Transcriptome Profiling Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Thermo Fisher Scientific, Inc. RNA Transcriptome Profiling Test Product Portfolio Table 47. Thermo Fisher Scientific, Inc. Recent Development Table 48. Illumina, Inc. Company Information Table 49. Illumina, Inc. Business Overview Table 50. Illumina, Inc. RNA Transcriptome Profiling Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Illumina, Inc. RNA Transcriptome Profiling Test Product Portfolio Table 52. Illumina, Inc. Recent Development Table 53. Agilent Technologies, Inc. Company Information Table 54. Agilent Technologies, Inc. Business Overview Table 55. Agilent Technologies, Inc. RNA Transcriptome Profiling Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Agilent Technologies, Inc. RNA Transcriptome Profiling Test Product Portfolio Table 57. Agilent Technologies, Inc. Recent Development Table 58. QIAGEN N.V. Company Information Table 59. QIAGEN N.V. Business Overview Table 60. QIAGEN N.V. RNA Transcriptome Profiling Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. QIAGEN N.V. RNA Transcriptome Profiling Test Product Portfolio Table 62. QIAGEN N.V. Recent Development Table 63. F. Hoffmann-La Roche AG Company Information Table 64. F. Hoffmann-La Roche AG Business Overview Table 65. F. Hoffmann-La Roche AG RNA Transcriptome Profiling Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. F. Hoffmann-La Roche AG RNA Transcriptome Profiling Test Product Portfolio Table 67. F. Hoffmann-La Roche AG Recent Development Table 68. Bio-Rad Laboratories, Inc. Company Information Table 69. Bio-Rad Laboratories, Inc. Business Overview Table 70. Bio-Rad Laboratories, Inc. RNA Transcriptome Profiling Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Bio-Rad Laboratories, Inc. RNA Transcriptome Profiling Test Product Portfolio Table 72. Bio-Rad Laboratories, Inc. Recent Development Table 73. Merck KGaA Company Information Table 74. Merck KGaA Business Overview Table 75. Merck KGaA RNA Transcriptome Profiling Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Merck KGaA RNA Transcriptome Profiling Test Product Portfolio Table 77. Merck KGaA Recent Development Table 78. Eurofins Scientific Company Information Table 79. Eurofins Scientific Business Overview Table 80. Eurofins Scientific RNA Transcriptome Profiling Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Eurofins Scientific RNA Transcriptome Profiling Test Product Portfolio Table 82. Eurofins Scientific Recent Development Table 83. Pacific Biosciences of California, Inc. Company Information Table 84. Pacific Biosciences of California, Inc. Business Overview Table 85. Pacific Biosciences of California, Inc. RNA Transcriptome Profiling Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Pacific Biosciences of California, Inc. RNA Transcriptome Profiling Test Product Portfolio Table 87. Pacific Biosciences of California, Inc. Recent Development Table 88. Promega Corporation Company Information Table 89. Promega Corporation Business Overview Table 90. Promega Corporation RNA Transcriptome Profiling Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Promega Corporation RNA Transcriptome Profiling Test Product Portfolio Table 92. Promega Corporation Recent Development Table 93. 10x Genomics Company Information Table 94. 10x Genomics Business Overview Table 95. 10x Genomics RNA Transcriptome Profiling Test Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. 10x Genomics RNA Transcriptome Profiling Test Product Portfolio Table 97. 10x Genomics Recent Development Table 98. Twist Bioscience Company Information Table 99. Twist Bioscience Business Overview Table 100. Twist Bioscience RNA Transcriptome Profiling Test Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Twist Bioscience RNA Transcriptome Profiling Test Product Portfolio Table 102. Twist Bioscience Recent Development Table 103. Bruker Spatial Biology Company Information Table 104. Bruker Spatial Biology Business Overview Table 105. Bruker Spatial Biology RNA Transcriptome Profiling Test Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Bruker Spatial Biology RNA Transcriptome Profiling Test Product Portfolio Table 107. Bruker Spatial Biology Recent Development Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. RNA Transcriptome Profiling Test Product Image Figure 2. Global RNA Transcriptome Profiling Test Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global RNA Transcriptome Profiling Test Market Size (2021-2032) & (US$ Million) Figure 4. Global RNA Transcriptome Profiling Test Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Consumables Image Figure 8. Instruments Image Figure 9. Software Image Figure 10. Services Image Figure 11. Global RNA Transcriptome Profiling Test Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global RNA Transcriptome Profiling Test Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global RNA Transcriptome Profiling Test Sales Value Share by Type (2021-2032) Figure 14. Hospital Based Laboratories Image Figure 15. Diagnostic Centers Image Figure 16. Academic and Research Institutes Image Figure 17. Contract research Organizations (CROs) Image Figure 18. Others Image Figure 19. Global RNA Transcriptome Profiling Test Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global RNA Transcriptome Profiling Test Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global RNA Transcriptome Profiling Test Sales Value Share by Application (2021-2032) Figure 22. Global RNA Transcriptome Profiling Test Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global RNA Transcriptome Profiling Test Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America RNA Transcriptome Profiling Test Sales Value (2021-2032) & (US$ Million) Figure 25. North America RNA Transcriptome Profiling Test Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe RNA Transcriptome Profiling Test Sales Value (2021-2032) & (US$ Million) Figure 27. Europe RNA Transcriptome Profiling Test Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific RNA Transcriptome Profiling Test Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific RNA Transcriptome Profiling Test Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America RNA Transcriptome Profiling Test Sales Value (2021-2032) & (US$ Million) Figure 31. South America RNA Transcriptome Profiling Test Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa RNA Transcriptome Profiling Test Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa RNA Transcriptome Profiling Test Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Consumables
  • Instruments
  • Software
  • Services
Applications
  • Hospital Based Laboratories
  • Diagnostic Centers
  • Academic and Research Institutes
  • Contract research Organizations (CROs)
  • Others
Companies covered
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • QIAGEN N.V.
  • F. Hoffmann-La Roche AG
  • Bio-Rad Laboratories, Inc.
  • Merck KGaA
  • Eurofins Scientific
  • Pacific Biosciences of California, Inc.
  • Promega Corporation
  • 10x Genomics
  • Twist Bioscience
  • Bruker Spatial Biology

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global RNA Transcriptome Profiling Test Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global RNA Transcriptome Profiling Test Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 RNA Transcriptome Profiling Test Market Dynamics
  1. 2.1 RNA Transcriptome Profiling Test Industry Trends
  2. 2.2 RNA Transcriptome Profiling Test Industry Drivers
  3. 2.3 RNA Transcriptome Profiling Test Industry Opportunities and Challenges
  4. 2.4 RNA Transcriptome Profiling Test Industry Restraints
3 RNA Transcriptome Profiling Test Market by Company
  1. 3.1 Global RNA Transcriptome Profiling Test Company Revenue Ranking in 2025
  2. 3.2 Global RNA Transcriptome Profiling Test Revenue by Company (2021-2026)
  3. 3.3 Global RNA Transcriptome Profiling Test Company Ranking (2024-2026)
  4. 3.4 Global RNA Transcriptome Profiling Test Company Manufacturing Base and Headquarters
  5. 3.5 Global RNA Transcriptome Profiling Test Company Product Type and Application
  6. 3.6 Global RNA Transcriptome Profiling Test Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global RNA Transcriptome Profiling Test Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 RNA Transcriptome Profiling Test Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 RNA Transcriptome Profiling Test Market by Type
  1. 4.1 RNA Transcriptome Profiling Test Type Introduction
  2. 4.1.1 Consumables
  3. 4.1.2 Instruments
  4. 4.1.3 Software
  5. 4.1.4 Services
  6. 4.2 Global RNA Transcriptome Profiling Test Sales Value by Type
  7. 4.2.1 Global RNA Transcriptome Profiling Test Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global RNA Transcriptome Profiling Test Sales Value by Type (2021-2032)
  9. 4.2.3 Global RNA Transcriptome Profiling Test Sales Value Share by Type (2021-2032)
5 RNA Transcriptome Profiling Test Market by Application
  1. 5.1 RNA Transcriptome Profiling Test Application Introduction
  2. 5.1.1 Hospital Based Laboratories
  3. 5.1.2 Diagnostic Centers
  4. 5.1.3 Academic and Research Institutes
  5. 5.1.4 Contract research Organizations (CROs)
  6. 5.1.5 Others
  7. 5.2 Global RNA Transcriptome Profiling Test Sales Value by Application
  8. 5.2.1 Global RNA Transcriptome Profiling Test Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global RNA Transcriptome Profiling Test Sales Value by Application (2021-2032)
  10. 5.2.3 Global RNA Transcriptome Profiling Test Sales Value Share by Application (2021-2032)
6 RNA Transcriptome Profiling Test Regional Value Analysis
  1. 6.1 Global RNA Transcriptome Profiling Test Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global RNA Transcriptome Profiling Test Sales Value by Region (2021-2032)
  3. 6.2.1 Global RNA Transcriptome Profiling Test Sales Value by Region: 2021-2026
  4. 6.2.2 Global RNA Transcriptome Profiling Test Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America RNA Transcriptome Profiling Test Sales Value (2021-2032)
  7. 6.3.2 North America RNA Transcriptome Profiling Test Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe RNA Transcriptome Profiling Test Sales Value (2021-2032)
  10. 6.4.2 Europe RNA Transcriptome Profiling Test Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific RNA Transcriptome Profiling Test Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific RNA Transcriptome Profiling Test Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America RNA Transcriptome Profiling Test Sales Value (2021-2032)
  16. 6.6.2 South America RNA Transcriptome Profiling Test Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa RNA Transcriptome Profiling Test Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa RNA Transcriptome Profiling Test Sales Value Share by Country, 2025 VS 2032
7 RNA Transcriptome Profiling Test Country-level Value Analysis
  1. 7.1 Global RNA Transcriptome Profiling Test Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global RNA Transcriptome Profiling Test Sales Value by Country (2021-2032)
  3. 7.2.1 Global RNA Transcriptome Profiling Test Sales Value by Country (2021-2026)
  4. 7.2.2 Global RNA Transcriptome Profiling Test Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt RNA Transcriptome Profiling Test Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt RNA Transcriptome Profiling Test Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt RNA Transcriptome Profiling Test Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Thermo Fisher Scientific, Inc.
  2. 8.1.1 Thermo Fisher Scientific, Inc. Company Information
  3. 8.1.2 Thermo Fisher Scientific, Inc. Business Overview
  4. 8.1.3 Thermo Fisher Scientific, Inc. RNA Transcriptome Profiling Test Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Thermo Fisher Scientific, Inc. RNA Transcriptome Profiling Test Product Portfolio
  6. 8.1.5 Thermo Fisher Scientific, Inc. Recent Developments
  7. 8.2 Illumina, Inc.
  8. 8.2.1 Illumina, Inc. Company Information
  9. 8.2.2 Illumina, Inc. Business Overview
  10. 8.2.3 Illumina, Inc. RNA Transcriptome Profiling Test Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Illumina, Inc. RNA Transcriptome Profiling Test Product Portfolio
  12. 8.2.5 Illumina, Inc. Recent Developments
  13. 8.3 Agilent Technologies, Inc.
  14. 8.3.1 Agilent Technologies, Inc. Company Information
  15. 8.3.2 Agilent Technologies, Inc. Business Overview
  16. 8.3.3 Agilent Technologies, Inc. RNA Transcriptome Profiling Test Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Agilent Technologies, Inc. RNA Transcriptome Profiling Test Product Portfolio
  18. 8.3.5 Agilent Technologies, Inc. Recent Developments
  19. 8.4 QIAGEN N.V.
  20. 8.4.1 QIAGEN N.V. Company Information
  21. 8.4.2 QIAGEN N.V. Business Overview
  22. 8.4.3 QIAGEN N.V. RNA Transcriptome Profiling Test Revenue and Gross Margin (2021-2026)
  23. 8.4.4 QIAGEN N.V. RNA Transcriptome Profiling Test Product Portfolio
  24. 8.4.5 QIAGEN N.V. Recent Developments
  25. 8.5 F. Hoffmann-La Roche AG
  26. 8.5.1 F. Hoffmann-La Roche AG Company Information
  27. 8.5.2 F. Hoffmann-La Roche AG Business Overview
  28. 8.5.3 F. Hoffmann-La Roche AG RNA Transcriptome Profiling Test Revenue and Gross Margin (2021-2026)
  29. 8.5.4 F. Hoffmann-La Roche AG RNA Transcriptome Profiling Test Product Portfolio
  30. 8.5.5 F. Hoffmann-La Roche AG Recent Developments
  31. 8.6 Bio-Rad Laboratories, Inc.
  32. 8.6.1 Bio-Rad Laboratories, Inc. Company Information
  33. 8.6.2 Bio-Rad Laboratories, Inc. Business Overview
  34. 8.6.3 Bio-Rad Laboratories, Inc. RNA Transcriptome Profiling Test Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bio-Rad Laboratories, Inc. RNA Transcriptome Profiling Test Product Portfolio
  36. 8.6.5 Bio-Rad Laboratories, Inc. Recent Developments
  37. 8.7 Merck KGaA
  38. 8.7.1 Merck KGaA Company Information
  39. 8.7.2 Merck KGaA Business Overview
  40. 8.7.3 Merck KGaA RNA Transcriptome Profiling Test Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Merck KGaA RNA Transcriptome Profiling Test Product Portfolio
  42. 8.7.5 Merck KGaA Recent Developments
  43. 8.8 Eurofins Scientific
  44. 8.8.1 Eurofins Scientific Company Information
  45. 8.8.2 Eurofins Scientific Business Overview
  46. 8.8.3 Eurofins Scientific RNA Transcriptome Profiling Test Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eurofins Scientific RNA Transcriptome Profiling Test Product Portfolio
  48. 8.8.5 Eurofins Scientific Recent Developments
  49. 8.9 Pacific Biosciences of California, Inc.
  50. 8.9.1 Pacific Biosciences of California, Inc. Company Information
  51. 8.9.2 Pacific Biosciences of California, Inc. Business Overview
  52. 8.9.3 Pacific Biosciences of California, Inc. RNA Transcriptome Profiling Test Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pacific Biosciences of California, Inc. RNA Transcriptome Profiling Test Product Portfolio
  54. 8.9.5 Pacific Biosciences of California, Inc. Recent Developments
  55. 8.10 Promega Corporation
  56. 8.10.1 Promega Corporation Company Information
  57. 8.10.2 Promega Corporation Business Overview
  58. 8.10.3 Promega Corporation RNA Transcriptome Profiling Test Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Promega Corporation RNA Transcriptome Profiling Test Product Portfolio
  60. 8.10.5 Promega Corporation Recent Developments
  61. 8.11 10x Genomics
  62. 8.11.1 10x Genomics Company Information
  63. 8.11.2 10x Genomics Business Overview
  64. 8.11.3 10x Genomics RNA Transcriptome Profiling Test Revenue and Gross Margin (2021-2026)
  65. 8.11.4 10x Genomics RNA Transcriptome Profiling Test Product Portfolio
  66. 8.11.5 10x Genomics Recent Developments
  67. 8.12 Twist Bioscience
  68. 8.12.1 Twist Bioscience Company Information
  69. 8.12.2 Twist Bioscience Business Overview
  70. 8.12.3 Twist Bioscience RNA Transcriptome Profiling Test Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Twist Bioscience RNA Transcriptome Profiling Test Product Portfolio
  72. 8.12.5 Twist Bioscience Recent Developments
  73. 8.13 Bruker Spatial Biology
  74. 8.13.1 Bruker Spatial Biology Company Information
  75. 8.13.2 Bruker Spatial Biology Business Overview
  76. 8.13.3 Bruker Spatial Biology RNA Transcriptome Profiling Test Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Bruker Spatial Biology RNA Transcriptome Profiling Test Product Portfolio
  78. 8.13.5 Bruker Spatial Biology Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research